₹ 1195 - ₹ 1258
09-Feb-2024 - 13-Feb-2024
₹ 13838.00



09-Feb-2024 - 13-Feb-2024

₹ 1195 - ₹ 1258

Price Band

₹ 13838.00

Minimum Investment


Bid Lot


  • Face Value - ₹ 10/- Per Share

  • Listing at NSE BSE

  • 115,045 Application Required in Retail for 1 Time.

  • Registrar : Link Intime India Private Ltd

IPO Details

Fresh Issue of Equity Shares aggregating upto Rs.1,000 Cr + Offer for Sale of upto 4,769,475 Equity Shares

Category % Shares/Amount
QIB 75% 9,491,256 Shares Rs.1194.00 Cr
HNI 1 5% 632,750 Shares Rs.79.60 Cr @ 3835 Form 1X
HNI 2 10% 1,265,501 Shares Rs.159.20 Cr @ 7670 Form 1X
Retail 10% 1,265,500 Shares Rs.159.20 Cr @ 115045 Form 1x

ICICI Securities, DAM Capital, Jefferies India ,JM Financial, SBI Capital Markets

Application Require for 1 Time

Retail (Upto 2 Lakh) HNI (2 Lakh to 10 Lakh) HNI (Above 10 Lakh)
115045 Form 1x 3835 Form 1X 7670 Form 1X

IPO Lot Size

Category Lots Shares Amount
Retail (Upto 2 Lakh) 1 11 ₹ 13,838
Retail (Upto 2 Lakh) 14 154 ₹ 193,732
S-HNI (2 Lakh to 10 Lakh) 15 165 ₹ 207,570
S-HNI (2 Lakh to 10 Lakh) 72 792 ₹ 996,336
B-HNI (Above 10 Lakh) 73 803 ₹ 1,010,174

IPO Timeline

  • Open Date

  • Close Date

  • Basis of Allotment Date

  • Initiation of Refunds

  • Credit Shares to Demat A/c

  • IPO Listing Date


Subscription as on
13-Feb-2024 14:15

Category Book Size Subscription No. of Times
QIB 3,796,503 ₹ 477.60 Cr. 8,023,026 ₹ 1009.30 Cr. 2.11x
HNI (<10 LAKH) 632,750 ₹ 79.60 Cr. 161,942 ₹ 20.37 Cr. 0.26x
HNI2 (>10 LAKH) 1,265,501 ₹ 159.20 Cr. 127,633 ₹ 16.06 Cr. 0.10x
RETAIL 1,265,500 ₹ 159.20 Cr. 1,547,414 ₹ 194.66 Cr. 1.22x
Total 6,960,254 9,860,015 1.42x
Category Book Size Subscription No. of Times
QIB 3,796,503 ₹ 477.60 Cr. 8,023,026 ₹ 1009.30 Cr. 2.11x
HNI (<10 LAKH) 632,750 ₹ 79.60 Cr. 161,942 ₹ 20.37 Cr. 0.26x
HNI2 (>10 LAKH) 1,265,501 ₹ 159.20 Cr. 127,633 ₹ 16.06 Cr. 0.10x
RETAIL 1,265,500 ₹ 159.20 Cr. 1,547,414 ₹ 194.66 Cr. 1.22x
Total 6,960,254 9,860,015 1.42x

*Excluding Anchor

Total No. of Application Approx : ~108858 (0.95 Appwise)

Disclaimer: The above-mentioned information / data are sourced from the websites of National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) and are subject to change on real time basis. For updated information / data you can visit their respective website. The information / data provided herein above are for information purpose only and provided "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied. We do not guarantee or warrant the accuracy, adequacy or completeness of the information received through the said websites. “We” hold not responsibility of any kind as regard to any discrepancies, errors, omissions, losses or damages. “We” including its affiliates and any of its officers, directors, personnel and employees, shall not liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any way arising from the use of information / data received through the said websites. The recipient alone shall be fully responsible / are liable for any decision taken on the basis of such information / data. All recipients should before acting upon the said information make their own investigation, seek appropriate professional advice.

About Company

  • Entero Healthcare Solutions Limited (“Entero”) was incorporated on January 10, 2018. Entero is a wholesale distribution healthcare platform which caters to retail pharmacies, hospitals, nursing homes, clinics, and physicians.

  • In addition, it also offers marketing and promotion services, patient support & access services to pharmaceutical and medical device companies. Furthermore, it provides technology solutions to retailers and distributors across the pharma value chain to help order management, inventory management etc.

  • Entero has nationwide presence of 77 distribution warehouses located across 38 cities in 19 states and union territories, and a customer base of over 73,700 pharmacies and 2,800 hospitals spread across 501 districts, as of September 30, 2023

  • Entero is among the top-3 healthcare products distributor in India in terms of revenue in fiscal 2022. The company reported operating income of ?3,300.21 crore in fiscal 2023.

  • Entero has achieved fastest scale up of operations among the healthcare products distributors in India (between fiscal 2019 to fiscal 2022). Entero reached ?2,500 crore operating income within 4 years of operations. Entero leverages technology to provide a positive buying experience through their digital solutions such as the Entero Direct B2B application (“Entero Direct”),

  • Entero is among the Top-3 healthcare products distributor in India to have wide network reach with retail pharmacies in India. Entero catered to 39,500+, 64,200+, 81,400+, 65,000+ and 73,700+ retail pharmacies in fiscal 2021, fiscal 2022, fiscal 2023, 6 months ended September 2022 and 6 months ended September 2023, respectively.

  • Entero has the largest hospital customer network among the pharmaceutical products distributors in India. Entero catered to 1600+, 2,500+, 3,400+, 2,400+ and 2,800+ hospital customers in fiscal 2021, fiscal 2022, fiscal 2023, 6 months ended September 2022 and 6 months ended September 2023, respectively.

  • The market share for Entero in Indian pharmaceutical and medical devices distribution industry (total size: 2,66,904 crore) is 1.24% as of fiscal 2023.

  • They have entered into an agreement with Roche Products (India) Pvt Ltd for the promotion, marketing, and distribution of its 4 nephrology drugs in India.

Read More


Competitive Strength 

  • The Company operates in the large and highly fragmented Indian healthcare products distribution market and expect to benefit from market consolidation;

  • One of India’s largest and fastest growing healthcare products distribution platforms;

  • Track record of inorganic expansion and integration to grow the geographic reach, revenues and scale;

  • Differentiated business model offering comprehensive and integrated commercial and supply chain solutions;

  • Proprietary technology platform with integrated business intelligence tools and solutions;

  • Experienced, committed and qualified founding and professional management team with deep industry expertise and backed by healthcare focused investor.

Business Strategies 

  • Benefit from healthcare products distribution market consolidation with strategic acquisitions;
  • Strengthen market position through increases in customer base, wallet share and geographic penetration;
  • Pursue comprehensive marketing and distribution collaborations with healthcare product manufacturers;
  • Expand the product adjacencies, private label and service offerings;
  • Continue to invest in and leverage the technology, scale and synergistic adjacencies to drive efficiencies and profitability.

Company Promoters

Sujesh Vasudevan is the Chairperson and Non-Executive Independent Director of the company. Prabhat Agrawal is the Promoter, Managing Director and Chief Executive Officer of the company Prem Sethi is the Promoter, Whole-time Director and Chief Operating Officer of the company. Sumona Chakraborty is a Non-Executive Non-Independent (Nominee) Director of the company Vipul Indravadan Desai is a Non-Executive Non-Independent (Nominee) Director of the company Arun Sadhanandham is a Non-Executive N

Company Financials

Entero Healthcare Solutions Limited's revenue increased by 30.84% and profit after tax (PAT) rose by 62.28% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended 31 Mar 2023 31 Mar 2022 31 Mar 2021
Assets 1,308.73 1,125.98 833.79
Revenue 3,305.72 2,526.55 1,783.67
Profit After Tax -11.10 -29.44 -15.35
Net Worth 597.66 563.22 487.06
Total Borrowing 373.52 285.03 141.70
Amount in ? Crore

Objects of the Issue

The Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

  • Repayment/prepayment, in full or part, of certain borrowings availed of by the company and our Subsidiaries.
  • Funding the long term working capital requirements.
  • Pursuing inorganic growth initiatives through acquisitions.
  • General corporate purposes.

How to Apply

Apply for IPO in few simple steps.

  • Step 01 :

    Once you create your account, Login to InvestoYard.

  • Step 02 :

    Under IPO Section, you will be able to see a list of Ongoing IPOs, where you can click on apply button.

  • Step 03 :

    Add quantity of shares to apply – Maximum 3 bids are allowed (For retail category – max amount Rs.2,00,000/-).

  • Step 04 :

    Enter your UPI ID and you will receive mandate on your UPI App.

  • Step 05 :

    Once you accept the mandate, Application is submitted successful.

  • Applying for an IPO is easier than ever with InvestoYard, in just a few clicks your application is processed. You can bid for any IPO through InvestoYard, the bidding process is simple and hassle free. Every company has a lot size decided & you can buy in multiples of the decided lot.
  • If lot size is 15, then you have to bid for multiples of 15 share like 30,45,60 and so on.
  • The maximum subscription amount for retail investors is 2 lakh.
  • Any bid can be at a desired price or cut off price given by the company.

  • Enter the number of shares you wish to buy, as per the lot size.
  • You can apply at the cut off price set by the company or bid for a desired amount within the price band.
  • Maximum three bids will be accepted.
  • You then need to enter the UPI ID on InvestoYard’s IPO application form.

  • You will immediately get a fund blocked request on your UPI for the submitted IPO application.
  • The funds will be blocked in your bank account until allotment when it is debited.
  • The limit for IPO application is Rs 2 lakh per transaction on UPI.
  • On allotment of the shares, the money will be automatically debited.
  • If the share aren’t allotted the blocked funds will reflect back into your account.

Frequently Asked Questions

Check Allotment